After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

It is available only through a restricted REMS program. The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults ...

The FDA has approved Johnson & Johnson’s (J&J) Spravato (esketamine) CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD). According to ...

Approval of Spravato, granted following FDA priority review, was based on the results of a randomized, double-blind, multicenter, placebo-controlled trial. On day 28 of the trial, patients taking ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

(WXYZ) — In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression. It's called Spravato, made by Johnson ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday. MDD ...